• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一家机构的早期和局部晚期非小细胞肺癌的总生存率:2000-2017 年。

Overall survival for early and locally advanced non-small-cell lung cancer from one institution: 2000-2017.

机构信息

Universidad Autónoma de Madrid, Madrid, Spain.

Medical Oncology Department, Hospital Universitario Puerta de Hierro, C/Manuel de Falla, Majadahonda, 28222, Madrid, Spain.

出版信息

Clin Transl Oncol. 2021 Jul;23(7):1325-1333. doi: 10.1007/s12094-020-02521-5. Epub 2021 Feb 2.

DOI:10.1007/s12094-020-02521-5
PMID:33528811
Abstract

PURPOSE

Lung cancer is the leading cause of cancer death in Spain. The objective of our study was to evaluate the characteristics of patients diagnosed with stages I-III non-small-cell lung cancer, as well as the impact that epidemiological changes, diagnostic improvements and surgical therapeutic innovations have had on survival in the past 20 years.

METHODS

Retrospective analysis of patients diagnosed with early and locally advanced non-small-cell lung cancer between years 2000 and 2017 in our institution.

RESULTS

A total of 859 patients were included. An increase in the percentage of women diagnosed over time was observed. Statistically significant differences were observed in the mean age at diagnosis, with a progressive increase in the different periods. The percentage of current or former smokers was similar in all periods. Adenocarcinoma was the most frequent histologic type with a progressive increase in its frequency. The percentage of patients diagnosed in early stages has been increasing over the years. In stages I-II, there was a significant increase in the median survival (29.7 months: 2000-2004, 68.73 months: 2010-2014) that could be seen in stage III as well (14.7 months: 2000-2004, 30.63 months: 2015-2017).

CONCLUSIONS

A variation of clinical characteristics of lung cancer in Spain has been observed in recent years, as well as an improvement in survival in early and locally advanced stages, due not only to the treatments, but also to a more accurate detection of these tumors. Little progress has been made in tobacco habit with high stable percentages over the years.

摘要

目的

肺癌是导致西班牙癌症死亡的主要原因。我们的研究目的是评估 I 期至 III 期非小细胞肺癌患者的特征,以及过去 20 年中流行病学变化、诊断改进和手术治疗创新对生存的影响。

方法

回顾性分析 2000 年至 2017 年期间在我院诊断为早期和局部晚期非小细胞肺癌的患者。

结果

共纳入 859 例患者。随着时间的推移,诊断为女性的患者比例有所增加。在诊断时的平均年龄方面观察到了统计学上的显著差异,不同时期的平均年龄呈递增趋势。各时期的现吸烟者或前吸烟者比例相似。腺癌是最常见的组织学类型,其频率呈递增趋势。诊断为早期阶段的患者比例逐年增加。在 I 期和 II 期,中位生存期有显著提高(29.7 个月:2000-2004 年,68.73 个月:2010-2014 年),III 期也有显著提高(14.7 个月:2000-2004 年,30.63 个月:2015-2017 年)。

结论

近年来,西班牙肺癌的临床特征发生了变化,早期和局部晚期的生存率也有所提高,这不仅得益于治疗方法的改进,还得益于这些肿瘤更准确的检测。多年来,吸烟习惯一直保持着较高的稳定比例,几乎没有取得进展。

相似文献

1
Overall survival for early and locally advanced non-small-cell lung cancer from one institution: 2000-2017.一家机构的早期和局部晚期非小细胞肺癌的总生存率:2000-2017 年。
Clin Transl Oncol. 2021 Jul;23(7):1325-1333. doi: 10.1007/s12094-020-02521-5. Epub 2021 Feb 2.
2
[Prognostic factors of advanced stage non-small-cell lung cancer].[晚期非小细胞肺癌的预后因素]
Rev Pneumol Clin. 2017 Sep;73(4):180-187. doi: 10.1016/j.pneumo.2017.05.002. Epub 2017 Jul 26.
3
Clinical characteristics and survival in non-small cell lung cancer patients by smoking history: a population-based cohort study.基于人群的队列研究:吸烟史对非小细胞肺癌患者临床特征和生存的影响。
Acta Oncol. 2019 Nov;58(11):1618-1627. doi: 10.1080/0284186X.2019.1638521. Epub 2019 Aug 2.
4
Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience.单纯放疗用于医学上无法手术的Ⅰ期非小细胞肺癌:杜克大学的经验。
Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):149-54. doi: 10.1016/s0360-3016(97)00589-0.
5
Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.葡萄牙免疫治疗时代前晚期非小细胞肺癌的真实世界治疗模式和生存结局:来自 I-O Optimise 计划的回顾性分析。
BMC Pulm Med. 2020 Sep 10;20(1):240. doi: 10.1186/s12890-020-01270-z.
6
Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.根据美国癌症联合委员会(AJCC)第7版分期系统,T4 N0-3期非小细胞肺癌患者的生存结果及预后因素
Asian Pac J Cancer Prev. 2014;15(6):2465-72. doi: 10.7314/apjcp.2014.15.6.2465.
7
Epidemiological analysis of progression-free survival (PFS) and overall survival (OS) in non-small-cell lung cancer patients in Republic of Macedonia.马其顿共和国非小细胞肺癌患者无进展生存期(PFS)和总生存期(OS)的流行病学分析
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2013;34(3):49-61.
8
Evolution of Diagnoses, Survival, and Costs of Oncological Medical Treatment for Non-Small-Cell Lung Cancer over 20 Years in Osona, Catalonia.20 多年来,加泰罗尼亚奥索尼地区非小细胞肺癌的肿瘤治疗诊断、生存和费用演变。
Curr Oncol. 2024 Apr 9;31(4):2145-2157. doi: 10.3390/curroncol31040159.
9
[Treatment outcome of locally advanced stage IIIA/B lung cancer].[局部晚期IIIA/B期肺癌的治疗结果]
Medicina (Kaunas). 2009;45(6):452-9.
10
Phase II study of vinorelbine plus carboplatin with concurrent radiotherapy in elderly patients with non-small cell lung cancer.长春瑞滨联合卡铂同期放疗治疗老年非小细胞肺癌的 II 期研究。
Jpn J Clin Oncol. 2020 Mar 9;50(3):318-324. doi: 10.1093/jjco/hyz179.

引用本文的文献

1
Long-term outcome of definitive radiotherapy for locally advanced non-small cell lung cancer: A real-world single-center study in the pre-durvalumab era.局部晚期非小细胞肺癌根治性放疗的长期疗效:durvalumab 时代前真实世界单中心研究。
Cancer Med. 2024 Aug;13(15):e70051. doi: 10.1002/cam4.70051.
2
Clinical factors influencing long-term survival in a real-life cohort of early stage non-small-cell lung cancer patients in Spain.影响西班牙早期非小细胞肺癌患者真实队列长期生存的临床因素。
Front Oncol. 2023 Feb 23;13:1074337. doi: 10.3389/fonc.2023.1074337. eCollection 2023.
3
Hsa_circ_0092887 targeting miR-490-5p/UBE2T promotes paclitaxel resistance in non-small cell lung cancer.
Hsa_circ_0092887 通过靶向 miR-490-5p/UBE2T 促进非小细胞肺癌对紫杉醇的耐药性。
J Clin Lab Anal. 2023 Jan;37(1):e24781. doi: 10.1002/jcla.24781. Epub 2022 Dec 22.
4
Association between physical activity and health-related quality of life: time to deterioration model analysis in lung adenocarcinoma.体力活动与健康相关生活质量的关联:肺腺癌的恶化时间模型分析。
J Cancer Surviv. 2023 Dec;17(6):1769-1779. doi: 10.1007/s11764-022-01259-z. Epub 2022 Oct 4.
5
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.肺癌关键生物标志物的测定:西班牙的真实世界数据研究,具有人口统计学、临床、流行病学和病理学特征。
BMC Cancer. 2022 Jul 5;22(1):732. doi: 10.1186/s12885-022-09830-8.